List of Arymo Er drug patents
Arymo Er is owned by Zyla.
Arymo Er contains Morphine Sulfate.
Arymo Er has a total of 2 drug patents out of which 0 drug patents have expired.
Arymo Er was authorised for market use on 09 January, 2017.
Arymo Er is available in tablet, extended release;oral dosage forms.
Arymo Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Arymo Er are possible to be released after 01 July, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) | |
| US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(10 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
ARYMO ER family patents
4
United States
2
European Union
1
Hong Kong
1
Brazil
1
Japan
1
Denmark
1
EA
1
Canada
1
Mexico
1
Australia
1
Korea, Republic of
1
New Zealand
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic